- Home
- ORGN vs CRDL Comparison
ORGN vs CRDL Comparison
Compare ORGN & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- CRDL
- Stock Information
- Founded
- ORGN 2008
- CRDL 2017
- Country
- ORGN United States
- CRDL Canada
- Employees
- ORGN N/A
- CRDL N/A
- Industry
- ORGN Major Chemicals
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORGN Industrials
- CRDL Health Care
- Exchange
- ORGN Nasdaq
- CRDL Nasdaq
- Market Cap
- ORGN 124.1M
- CRDL 134.5M
- IPO Year
- ORGN N/A
- CRDL N/A
- Fundamental
- Price
- ORGN $1.40
- CRDL $1.81
- Analyst Decision
- ORGN Strong Buy
- CRDL Strong Buy
- Analyst Count
- ORGN 1
- CRDL 3
- Target Price
- ORGN $3.00
- CRDL $9.00
- AVG Volume (30 Days)
- ORGN 675.5K
- CRDL 653.0K
- Earning Date
- ORGN 11-07-2024
- CRDL 11-12-2024
- Dividend Yield
- ORGN N/A
- CRDL N/A
- EPS Growth
- ORGN N/A
- CRDL N/A
- EPS
- ORGN N/A
- CRDL N/A
- Revenue
- ORGN $34,061,000.00
- CRDL N/A
- Revenue This Year
- ORGN $10.62
- CRDL N/A
- Revenue Next Year
- ORGN $175.99
- CRDL N/A
- P/E Ratio
- ORGN N/A
- CRDL N/A
- Revenue Growth
- ORGN 295.97
- CRDL N/A
- 52 Week Low
- ORGN $0.44
- CRDL $0.72
- 52 Week High
- ORGN $1.90
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- ORGN 45.07
- CRDL 41.05
- Support Level
- ORGN $1.34
- CRDL $1.78
- Resistance Level
- ORGN $1.50
- CRDL $1.95
- Average True Range (ATR)
- ORGN 0.07
- CRDL 0.08
- MACD
- ORGN -0.01
- CRDL -0.00
- Stochastic Oscillator
- ORGN 35.00
- CRDL 21.11
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.